Literature DB >> 19571789

Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1.

Sonia Fargue1, Jérôme Harambat, Marie-France Gagnadoux, Michel Tsimaratos, Françoise Janssen, Brigitte Llanas, Jean-Pierre Berthélémé, Bernard Boudailliez, Gérard Champion, Claude Guyot, Marie-Alice Macher, Hubert Nivet, Bruno Ranchin, Rémi Salomon, Sophie Taque, Marie-Odile Rolland, Pierre Cochat.   

Abstract

Primary hyperoxaluria type 1 results from alanine:glyoxylate aminotransferase deficiency. Due to genotype/phenotype heterogeneity in this autosomal recessive disorder, the renal outcome is difficult to predict in these patients and the long-term impact of conservative management in children is unknown. We report here a multicenter retrospective study on the renal outcome in 27 affected children whose biological diagnosis was based on either decreased enzyme activity or identification of mutations in the patient or his siblings. The median age at first symptoms was 2.4 years while that at initiation of conservative treatment was 4.1 years; 6 children were diagnosed upon family screening. The median follow-up was 8.7 years. At diagnosis, 15 patients had an estimated glomerular filtration rate (eGFR) below 90, and 7 children already had stage 2-3 chronic kidney disease. The median baseline eGFR was 74, which rose to 114 with management in the 22 patients who did not require renal replacement therapy. Overall, 20 patients had a stable eGFR, however, 7 exhibited a decline in eGFR of over 20 during the study period. In a Cox regression model, the only variable significantly associated with deterioration of renal function was therapeutic delay with a relative risk of 1.7 per year. Our study strongly suggests that early and aggressive conservative management may preserve renal function of compliant children with this disorder, thereby avoiding dialysis and postponing transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19571789     DOI: 10.1038/ki.2009.237

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  22 in total

1.  Pediatrics: Timely diagnosis of primary hyperoxaluria type 1.

Authors:  Alejandro Quiroga Chand; Frederick J Kaskel
Journal:  Nat Rev Nephrol       Date:  2009-12       Impact factor: 28.314

2.  End Points for Clinical Trials in Primary Hyperoxaluria.

Authors:  Dawn S Milliner; Tracy L McGregor; Aliza Thompson; Bastian Dehmel; John Knight; Ralf Rosskamp; Melanie Blank; Sixun Yang; Sonia Fargue; Gill Rumsby; Jaap Groothoff; Meaghan Allain; Melissa West; Kim Hollander; W Todd Lowther; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-12       Impact factor: 8.237

3.  A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.

Authors:  Bernd Hoppe; Patrick Niaudet; Rémi Salomon; Jérôme Harambat; Sally-Anne Hulton; William Van't Hoff; Shabbir H Moochhala; Georges Deschênes; Elisabeth Lindner; Anna Sjögren; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2016-12-06       Impact factor: 3.714

4.  Liver transplantation in oxalosis prior to advanced chronic kidney disease.

Authors:  Jon I Scheinman
Journal:  Pediatr Nephrol       Date:  2010-07-29       Impact factor: 3.714

5.  Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.

Authors:  Heike Hoyer-Kuhn; Sina Kohbrok; Ruth Volland; Jeremy Franklin; Barbara Hero; Bodo B Beck; Bernd Hoppe
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-02       Impact factor: 8.237

6.  Transplantation outcomes in primary hyperoxaluria.

Authors:  E J Bergstralh; C G Monico; J C Lieske; R M Herges; C B Langman; B Hoppe; D S Milliner
Journal:  Am J Transplant       Date:  2010-09-17       Impact factor: 8.086

7.  Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy.

Authors:  Jérôme Harambat; Karlijn J van Stralen; Laura Espinosa; Jaap W Groothoff; Sally-Anne Hulton; Rimante Cerkauskiene; Franz Schaefer; Enrico Verrina; Kitty J Jager; Pierre Cochat
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-05       Impact factor: 8.237

8.  Skin microvascular dysfunction as an early cardiovascular marker in primary hyperoxaluria type I.

Authors:  Alexandra Bruel; Justine Bacchetta; Tiphanie Ginhoux; Christelle Rodier-Bonifas; Anne-Laure Sellier-Leclerc; Bérengère Fromy; Pierre Cochat; Dominique Sigaudo-Roussel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

Review 9.  Primary hyperoxaluria type 1: practical and ethical issues.

Authors:  Pierre Cochat; Jaap Groothoff
Journal:  Pediatr Nephrol       Date:  2013-03-14       Impact factor: 3.714

10.  Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver-kidney transplantation for primary hyperoxaluria type 1.

Authors:  Eliza Lee; Gabriel Ramos-Gonzalez; Nancy Rodig; Scott Elisofon; Khashayar Vakili; Heung Bae Kim
Journal:  Pediatr Nephrol       Date:  2017-12-14       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.